News | August 30, 2021
Acute therapies drive overall pharma growth in July: Ind-Ra
The segment delivered strong sales growth of 20% YoY
The segment delivered strong sales growth of 20% YoY
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
To prevent the state from facing a shortage of medical oxygen and to bolster the existing infrastructure, the SRAM & MRAM group is actively helping the state government to set up oxygen plants in multiple cities
The company to receive upfront and milestone payments, in addition to royalties
Domestic business was up 41.9% YoY and 27.7% QoQ
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Subscribe To Our Newsletter & Stay Updated
